Print Friendly, PDF & Email


AGE-1 Glucose modified

Catalogue number: AGE1-010

Clone7C1
IsotypeIgG1,k
Units10 µg
HostMouse
Application ELISA
Western Blotting

Background
Glukose-modified AGEs (AGE-1) induce Apoptosis and Micro-albuminuria by destruction of mesangial cells of the human kidney. In this way they are responsible for the onset of early diabetic nephropathy. The antibody is well suited for the detection of AGE-1 in tissue extracts body fluids and cell culture media. Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) ß2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimer’s disease. These results suggested the potential role of AGE in normal aging and age-enhanced disease processes. Glukose modified AGE, in Western Blot no cross-reaction with AGE-2 (Glyceraldehyde modified), AGE-3 (Glycolaldehyde modified), AGE-4 (Methylglyoxal-modified), AGE-5 (Glyoxal-modied), AGE-6 (3-DG-modified), CEL-BSA, CML-BSA and BSA..

Source

Immunogen: AGE-1-BSA

Product
Protein G affinity purified monoclonal antibody in PBS with 2% Block Ace as stabilizer and 0.1% Proclin as preservative

Purification Method: Protein G affinity purified monoclonal antibody in PBS with 2% Block Ace as stabilizer and 0.1% Proclin as preservative

Concentration: 0.25 mg/ml

Secondary Reagents: As secondary system in ELISA and Western Blot we recommend biotinylated anti-mouse IgG antibody (Art. No. ZU102) in combination with streptavidin-HRPO conjugate (Art. No. ZU054) or streptavidin-alkaline phosphatase (Art. No. ZU051).

Specificity

Species Reactivity: Human

Applications
ELISA, WB

Incubation Time: 60 min at RT or 18 hr at 2-8°C

Working Concentration: (liquid conc.) 0,1 µg/ml (WB and ELISA)

Positive Control: human lens, arteriosclerotic plaques

Storage
-20°C

Caution
These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.

References
1. Takeuchi M. , Makita Z., Bucala R., Suzuki T., Koike T., and Kameda Y. (2000) Immunological evidence that non-carboxymethyllysine Advanced Glycation End-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol. Med. 6; 114-125. 2. Takeuchi M., Yanase Y., Matsuura N., Yamagishi S., Kameda Y., Bucala R., and Z. Matika (2001) Immunological detection of a novel Advanced Glycation End-Product. Mol. Med. 7; 783-791. 3. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., and Makita Z. (2002) Advanced Glycation End Products-Induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor in Bovine Retinal Pericytes Biochemical and Biophysical Research Communications ; 290, 973-978.


AGE-1 Glucose modified

$1,080.00

SKU: AGE1-010 Categories: ,

Brand

Contact us

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464
Phone: 978-425-1370
Email: info@exalpha.com

Member

Newsletter